Experimental Drug DT-109 Reverses Fatty Liver Disease by Healing the Gut

Metabolic dysfunction-associated steatohepatitis, or MASH, is a severe form of fatty liver disease that affects approximately 7% of the global population. It can silently progress to cirrhosis, liver cancer, and organ failure, yet approved treatment options remain limited. A new study published in The Journal of Clinical Investigation now offers a promising new direction, showing that an experimental compound called DT-109 can reverse MASH in animal models by repairing the gut-liver axis.

The research from Michigan Medicine identified a key biological chain of events driving MASH progression. An overgrowth of the gut bacterium Clostridium perfringens produces excess ammonia, which weakens the protective intestinal lining. Once this barrier is compromised, harmful microbial byproducts leak into the bloodstream, travel to the liver, and trigger inflammatory immune responses — including excessive activation of CD8+ T cells — accelerating liver damage.

DT-109 is a glycine-based tripeptide that interrupts this harmful cascade. In both mice and nonhuman primates, the compound reduced Clostridium perfringens levels, lowered intestinal ammonia production, and strengthened the gut epithelial barrier. This prevented the systemic translocation of pro-inflammatory microbial products, reducing liver inflammation and significantly improving MASH severity. Results in nonhuman primates were particularly notable given how closely their gut microbiota and liver biology resemble those of humans.

The findings suggest that targeting the gut-liver axis — rather than the liver alone — could represent a new therapeutic paradigm for MASH. By acting primarily in the gastrointestinal tract, DT-109 achieves systemic benefits, pointing to potential utility beyond MASH in other gut-health-related conditions.

Important caveats apply. All results so far come from animal studies, and human clinical trials have not yet been conducted. The pathway from promising animal data to approved human therapy is long and uncertain. Nevertheless, for health-conscious individuals, this research reinforces the growing evidence that gut microbiome health is deeply intertwined with metabolic and liver function.